TY - JOUR T1 - Cost-effectiveness of real-world administration of chemotherapy and add-on <em>Viscum album</em> L. therapy compared to chemotherapy alone in the treatment of stage IV NSCLC patients JF - medRxiv DO - 10.1101/2020.02.04.20020354 SP - 2020.02.04.20020354 AU - Anja Thronicke AU - Thomas Reinhold AU - Philipp von Trott AU - Christian Grah AU - Burkhard Matthes AU - Harald Matthes AU - Friedemann Schad Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/02/07/2020.02.04.20020354.abstract N2 - Background For stage IV lung cancer patients receiving add-on Viscum album L. treatment an improved overall survival (OS) was observed. Only limited information regarding cost-effectiveness (CE) for comparisons between standard of care and standard of care plus add-on VA in stage IV lung cancer treatment is available. The present study assessed the costs and cost-effectiveness of standard of care plus VA (V) compared to standard of care alone (C) for stage IV non-small cell lung cancer (NSCLC) patients treatment in a hospital in Germany.Methods An observational study was conducted using data from the Network Oncology clinical registry. Patients included had stage IV lung cancer at diagnosis and received C or V treatment in a certified German Cancer Center. Cost and cost-effectiveness analyses (CEA) including the analysis of the incremental cost-effectiveness ratios (ICER) were performed from the hospital’s perspective based on routine data from financial controlling department and observed data on OS. The primary result of the analysis was tested for robustness in a bootstrap-based sensitivity analysis.Results 118 patients (C: n=86, V: n=32) were included, mean age 63.8 years, proportion of male patients 55.1%. Adjusted hospital’s total mean costs for patients from the C and V group were €16,289 (over an adjusted mean OS time of 13.4 months) and €17,992 (over an adjusted mean OS time of 19.1 months), respectively. The costs per additional OS year gained (ICER) with the V-treatment compared to C were €3,586.Conclusion Based on our analysis, the assessment of inpatient costs and cost-effectiveness of IO concepts in stage IV lung cancer suggests that the combined use of chemotherapy and VA is clinically effective and was comparably cost-effective to chemotherapy alone in our analysed patient sample. Further randomized and prospective cost-effectiveness studies are mandatory to complement our findings.Competing Interest StatementCG reports grants from Iscador AG, outside the submitted work. BM received fees for lectures or advisory boards from AstraZeneca, Boehringer Ingelheim, Helixor, Kyowa-Kirin, Leo, Lilly, Roche, Teva, outside the submitted work. BM received grants for travelling from AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Helixor, Iscador, Janssen, Kyowa-Kirin, Leo, Lilly, Novartis, MSD, Pfizer, Roche, Teva. HM is a member of the board of directors of Weleda AG and a member of the Network Arbeitsgemeinschaft der Wissenschaftlichen Fachgesellschaften (AWMF e.V.) guideline committee for integrative oncology (Guideline for Complementary Medicine in the Treatment of Oncological Patients). HM has an endowed professorship at the Charité Universitatsmedizin Berlin, which is financed by the Software AG Foundation, outside the submitted work. FS reports grants from Helixor Heilmittel GmbH (travel costs and honoraria for speaking), grants from AstraZeneca (travel costs and honoraria for speaking), grants from Abnoba GmbH, grants from Iscador AG, outside the submitted work. The other authors have declared that no competing interests exist. No payment was received for any other aspects of the submitted work. There are no patents, products in development or marketed products to declare. There are no other relationships, conditions or circumstances that present a potential conflict of interest.Funding StatementThe Network Oncology was funded by unrestricted research grants from Iscador AG Arlesheim, Switzerland; Abnoba GmbH Pforzheim, Germany; and Helixor GmbH Rosenfeld, Germany. By contract, researchers were independent from the funder. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are within the manuscript and its supporting information files. ER -